1. Aas, T., Børresen, A. L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., et al. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine., 2(7), 811–814.
2. Alfano, C.M., Kevorkian, C.G., Miller, K.D., Siegel, R.L., Khan, R., & Jemal, A., et al. (2018). Cancer Rehabilitation [Internet]. Stubblefield MD, editor. Springer Publishing Company. 967 p. Available from: https://connect.springerpub.com/content/book/978-0-8261-2164-6
3. Amadou, A., Waddington Achatz, M. I., & Hainaut, P. (2018). Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: Temporal phases of Li–Fraumeni syndrome. Current Opinion in Oncology., 30(1), 23–29.
4. Amjad, M.T., Chidharla, A., & Kasi, A. (2021). Cancer chemotherapy. In: StatPearls [Internet]. StatPearls Publishing.
5. Andre, T. (2004). Multicenter international study of oxaliplatin/5-fluorouracil/leukovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators: Oxaliplatin, fluorouracil and leukovorin as adjuvant treatment for colon cancer. New England Journal of Medicine, 50, 2243–2251.